May 30 Financial Quick Takes: $200M series F for Tempus; plus TFF, Frontage Holdings

Tempus raises $200M for precision medicine platform
Bringing its valuation to $3.1 billion, Tempus Labs Inc. (Chicago, Ill.) raised $200 million in a series F round to expand its precision medicine platform into new therapeutic areas and geographies, bringing to $520 million its money raised since being founded in 2015. Participating in the round were Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth and T. Rowe Price-managed funds and accounts (see “Computing Care”).

TFF adds $8.2M to series A
Respiratory disease company TFF Pharmaceuticals Inc. (Austin, Texas) raised $8.2 million from undisclosed investors in the second tranche of its series A round; it raised $14 million in the round in 2018. TFF will use the funds to develop its pipeline of inhaled dry powder formulations of biologics and small molecules for pulmonary diseases. The company also announced Kirk Coleman as CFO. He previously was an executive officer of Steelhead Capital Management and of Bios Partners...